The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing
Open accessAbstract
Fluconazole in vitro susceptibility test results determined by the CLSI M44-A disk diffusion method for 11,240 isolates of noncandidal yeasts were collected from 134 study sites in 40 countries from June 1997 through December 2007. Data were collected for 8,717 yeast isolates tested with voriconazole from 2001 through 2007. A total of 22 different species/organism groups were isolated, of which Cryptococcus neoformans was the most common (31.2% of all isolates). Overall, Cryptococcus (32.9%), Saccharomyces (11.7%), Trichosporon (10.6%), and Rhodotorula (4.1%) were the most commonly identified genera. The overall percentages of isolates in each category (susceptible, susceptible dose dependent, and resistant) were 78.0%, 9.5%, and 12.5% and 92.7%, 2.3%, and 5.0% for fluconazole and voriconazole, respectively. Less than 30% of fluconazole-resistant isolates of Cryptococcus spp., Cryptococcus albidus , Cryptococcus laurentii , Trichosporon beigelii/Trichosporon cutaneum , Rhodotorula spp., Rhodotorula rubra/Rhodotorula mucilaginosa , and Rhodotorula glutinis remained susceptible to voriconazole. Emerging resistance to fluconazole was documented among isolates of C. neoformans from the Asia-Pacific, Africa/Middle East, and Latin American regions but not among isolates from Europe or North America. This survey documents the continuing broad spectrum of activity of voriconazole against opportunistic yeast pathogens but identifies several of the less common species with decreased azole susceptibility. These organisms may pose a future threat to optimal antifungal therapy and emphasize the importance of prompt and accurate species identification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 11×
“For the purposes of the study, we utilized the interpretive breakpoints for fluconazole and voriconazole that have been established for Candida (52, 53), and we recognize that they may need to be adjusted for noncandidal yeasts in the future.”
BackgroundInfluentialSelf-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Practice Guidelines for the Management of Cryptococcal Disease
Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D., Dismukes, W. E., & Mycoses Study Group Cryptococcal Subproject (2000) · Clinical Infectious Diseases · doi:10.1086/313757 · Cited by 1,105
Pappas, P. G., Rex, J. H., Lee, J., Hamill, R. J., Larsen, R. A., Powderly, W., Kauffman, C. A., Hyslop, N., Mangino, J. E., Chapman, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376906 · Cited by 845
Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784
Kidd, S. E., Hagen, F., Tscharke, R. L., Huynh, M., Bartlett, K. H., Fyfe, M., MacDougall, L., Boekhout, T., Kwon-Chung, K. J., & Meyer, W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402981101 · Cited by 756
Pfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694
Self-citationVoriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre‐Cisneros, J., Just‐Nubling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 680
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
New and emerging yeast pathogens
Hazen, K. C. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.462 · Cited by 614
Infections due to emerging and uncommon medically important fungal pathogens
Walsh, T. J., Groll, A., Hiemenz, J., Fleming, R., Roilides, E., & Anaissie, E. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00839.x · Cited by 601
Developments in Fungal Taxonomy
Guarro, J., Gené, J., & Stchigel, A. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.3.454 · Cited by 534
Saccharomyces cerevisiae Fungemia: An Emerging Infectious Disease
Munoz, P., Bouza, E., Cuenca-Estrella, M., Eiros, J. M., Perez, M. J., Sanchez-Somolinos, M., Rincon, C., Hortal, J., & Pelaez, T. (2005) · Clinical Infectious Diseases · doi:10.1086/429916 · Cited by 462
Invasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448
Self-citationNucci, M., & Marr, K. A. (2005) · Clinical Infectious Diseases · doi:10.1086/432060 · Cited by 435
Rees, J. R., Pinner, R. W., Hajjeh, R. A., Brandt, M. E., & Reingold, A. L. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1138 · Cited by 397
Girmenia, C., Pagano, L., Martino, B., D'Antonio, D., Fanci, R., Specchia, G., Melillo, L., Buelli, M., Pizzarelli, G., Venditti, M., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1818-1828.2005 · Cited by 397
Invasive Saccharomyces Infection: A Comprehensive Review
Enache-Angoulvant, A., & Hennequin, C. (2005) · Clinical Infectious Diseases · doi:10.1086/497832 · Cited by 369 · cited 1×
“cerevisiae from clinical specimens may reflect the practice of using the organism (subtype boulardii) as a probiotic in the treatment of antibiotic-associated diarrhea (19, 38).”
BackgroundHas antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361
Self-citationCryptococcus neoformans variety gattii
Sorrell, T. C. (2001) · Medical Mycology · doi:10.1080/mmy.39.2.155.168 · Cited by 307
Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., & Rodriguez-Tudela, J. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.917-921.2006 · Cited by 298
Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 295
Self-citationPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Meis, J. F., Gould, I. M., Fu, W., Colombo, A. L., & Rodriguez-Noriega, E. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00409-07 · Cited by 284
Self-citationHajjeh, R. A., Conn, L. A., Stephens, D. S., Baughman, W., Hamill, R., Graviss, E., Pappas, P. G., Thomas, C., Reingold, A., Rothrock, G., et al. (1999) · The Journal of Infectious Diseases · doi:10.1086/314606 · Cited by 275
Bicanic, T., Meintjes, G., Wood, R., Hayes, M., Rebe, K., Bekker, L.-G., & Harrison, T. (2007) · Clinical Infectious Diseases · doi:10.1086/518607 · Cited by 271
Pfaller, M. A., & Diekema, D. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3551-3557.2002 · Cited by 269
Self-citationPfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258
Self-citationCurrent Treatment Strategies for Disseminated Candidiasis
Spellberg, B. J., Filler, S. G., & Edwards, J. E. (2006) · Clinical Infectious Diseases · doi:10.1086/499057 · Cited by 256
Candida, Cryptococcus, and Other Yeasts of Medical Importance
Howell, S. A., & Hazen, K. C. (2011) · Manual of Clinical Microbiology · doi:10.1128/9781555816728.ch115 · Cited by 246
Pfaller, M. A., Diekema, D. J., Rinaldi, M. G., Barnes, R., Hu, B., Veselov, A. V., Tiraboschi, N., Nagy, E., & Gibbs, D. L. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.12.5848-5859.2005 · Cited by 228
Self-citationBicanic, T., Harrison, T., Niepieklo, A., Dyakopu, N., & Meintjes, G. (2006) · Clinical Infectious Diseases · doi:10.1086/507895 · Cited by 224
Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004)
Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Doern, G. V., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.5.2163-2167.2005 · Cited by 205
Self-citationPfaller, M. A., Diekema, D. J., Mendez, M., Kibbler, C., Erzsebet, P., Chang, S.-C., Gibbs, D. L., Newell, V. A., & the Global Antifungal Surveillance Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00865-06 · Cited by 194
Self-citationSusceptibility Patterns and Molecular Identification of Trichosporon Species
Rodriguez-Tudela, J. L., Diaz-Guerra, T. M., Mellado, E., Cano, V., Tapia, C., Perkins, A., Gomez-Lopez, A., Rodero, L., & Cuenca-Estrella, M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.10.4026-4034.2005 · Cited by 179
Arendrup, M. C., Fuursted, K., Gahrn-Hansen, B., Jensen, I. M., Knudsen, J. D., Lundgren, B., Schønheyder, H. C., & Tvede, M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.9.4434-4440.2005 · Cited by 178
Liebowitz, L. D., Ashbee, H. R., Evans, E. G. V., Chong, Y., Mallatova, N., Zaidi, M., & Gibbs, D. (2001) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(01)00243-7 · Cited by 175
Self-citationThe Changing Face of Fungal Infections in Health Care Settings
Weinstein, R. A., & Fridkin, S. K. (2005) · Clinical Infectious Diseases · doi:10.1086/497138 · Cited by 171
Spanakis, E. K., Aperis, G., & Mylonakis, E. (2006) · Clinical Infectious Diseases · doi:10.1086/507891 · Cited by 167
Breakthrough Trichosporonosis in Patients with Hematologic Malignancies Receiving Micafungin
Matsue, K., Uryu, H., Koseki, M., Asada, N., & Takeuchi, M. (2006) · Clinical Infectious Diseases · doi:10.1086/500323 · Cited by 156
Larsen, R. A., Bozzette, S., McCutchan, J. A., Chiu, J., Leal, M. A., Richman, D. D., & California Collaborative Treatment Group (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-2-125 · Cited by 150
Contemporary tools for the diagnosis and management of invasive mycoses
Alexander, B. D., & Pfaller, M. A. (2006) · Clinical Infectious Diseases · doi:10.1086/504491 · Cited by 147
Self-citationClinical Significance of Azole Antifungal Drug Cross-Resistance in Candida glabrata
Panackal, A. A., Gribskov, J. L., Staab, J. F., Kirby, K. A., Rinaldi, M. G., & Marr, K. A. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.5.1740-1743.2006 · Cited by 144
Magill, S. S., Shields, C. E., Sears, C. L., Choti, M. A., & Merz, W. G. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.529-535.2006 · Cited by 139
Risk of Fungemia Due to Rhodotorula and Antifungal Susceptibility Testing of Rhodotorula Isolates
Zaas, A. K., Boyce, M. K., Schell, W. A., Alexander, B. D., Miller, J. L., & Perfect, J. R. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.11.5233-5235.2003 · Cited by 134
Brandt, M. E., Pfaller, M. A., Hajjeh, R. A., Hamill, R. J., Pappas, P. G., Reingold, A. L., Rimland, D., & Warnock, D. W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3065-3069.2001 · Cited by 125
Self-citationSusceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review
Gómez‐López, A., Mellado, E., Rodríguez-Tudela, J. L., & Cuenca‐Estrella, M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki020 · Cited by 120
Sepsis Due to Rhodotorula Related to Use of Indwelling Central Venous Catheters
Kiehn, T. E., Gorey, E., Brown, A. E., Edwards, F. F., & Armstrong, D. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.4.841 · Cited by 120
Activities of Available and Investigational Antifungal Agents against Rhodotorula Species
Diekema, D. J., Petroelje, B., Messer, S. A., Hollis, R. J., & Pfaller, M. A. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.1.476-478.2005 · Cited by 117
Self-citationPfaller, M. A., Diekema, D. J., Colombo, A. L., Kibbler, C. C., Ng, K. P., Gibbs, D. L., Newell, V. A., & the Global Antifungal Surveillance Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00863-06 · Cited by 107
Self-citationSar, B. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh361 · Cited by 101
In Vitro Antifungal Susceptibility of Cryptococcus gattii
Trilles, L., Fernández-Torres, B., Lazéra, M. D. S., Wanke, B., & Guarro, J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4815-4817.2004 · Cited by 96
Hazen, K. C., Baron, E. J., Colombo, A. L., Girmenia, C., Sánchez-Sousa, A., del Palacio, A., de BEDOUT, C., & Gibbs, D. L. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5623-5632.2003 · Cited by 96
Self-citationBreakthrough Trichosporonosis in a Bone Marrow Transplant Recipient Receiving Caspofungin Acetate
Goodman, D., Pamer, E. G., Jakubowski, A. A., Morris, C. D., & Sepkowitz, K. A. (2002) · Clinical Infectious Diseases · doi:10.1086/341305 · Cited by 92
Pfaller, M. A., Boyken, L. B., Messer, S. A., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5208-5213.2005 · Cited by 90
Self-citationEpidemiology and Outcome of Rhodotorula Fungemia in a Tertiary Care Hospital
Lunardi, L. W., Aquino, V. R., Zimerman, R. A., & Goldani, L. Z. (2006) · Clinical Infectious Diseases · doi:10.1086/507036 · Cited by 89
A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion
Meis, J. F. G. M., Petrou, M. A., Billé, J., Ellis, D., & Gibbs, D. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00152-2 · Cited by 88
Self-citationMorgan, J., McCarthy, K., Gould, S., Fan, K., Arthington, B. A., Iqbal, N. J., Stamey, K., Hajjeh, R. A., Brandt, M. E., & Gauteng Cryptococcal Surveillance Initiative Group (2006) · Clinical Infectious Diseases · doi:10.1086/507897 · Cited by 87
Herbrecht, R., & Nivoix, Y. (2005) · Clinical Infectious Diseases · doi:10.1086/429926 · Cited by 83
Pfaller, M. A., Diekema, D. J., Procop, G. W., & Rinaldi, M. G. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01986-06 · Cited by 78
Self-citationPfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01551-06 · Cited by 77
Self-citationThe Hidden Danger of Primary Fluconazole Prophylaxis for Patients with AIDS
Berg, J., Clancy, C. J., & Nguyen, M. H. (1998) · Clinical Infectious Diseases · doi:10.1086/517056 · Cited by 70
Pfaller, M. A., & Jones, R. N. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-767-paoaaa · Cited by 70
Self-citationAntifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya
Bii, C. C., Makimura, K., Abe, S., Taguchi, H., Mugasia, O. M., Revathi, G., Wamae, N., & Kamiya, S. (2006) · Mycoses · doi:10.1111/j.1439-0507.2006.01293.x · Cited by 67
Antifungal Susceptibilities ofCryptococcus neoformans
Archibald, L. K., Tuohy, M. J., Wilson, D. A., Nwanyanwu, O. C., Kazembe, P. N., Tansuphasawadikul, S., Eampokalap, B., Chaovavanich, A., Reller, L. B., Jarvis, W. R., et al. (2004) · Emerging infectious diseases · doi:10.3201/eid1001.020779 · Cited by 65
Chen, A. L., & Sobel, J. D. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.21 · Cited by 65
Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis
Bicanic, T. A., Wood, R., Bekker, L., Darder, M., Meintjes, G., & Harrison, T. S. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70197-3 · Cited by 63
Calvo, B., Colombo, A. L., Fischman, O., Santiago, A. Z. F. S., Thompson, L., Lazéra, M. D. S., Telles, F. D. Q., Fukushima, K., Nishimura, K., Tanaka, R., et al. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.6.2348-2350.2001 · Cited by 59
Perkins, A., Gómez‐López, A., Mellado, E., Rodrı́guez-Tudela, J. L., & Cuenca‐Estrella, M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki393 · Cited by 58
Pfaller, M. A., Hazen, K. C., Messer, S. A., Boyken, L. B., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.8.3607-3612.2004 · Cited by 55
Self-citationChandenier, J., Adoubryn, K. D., Douchet, C., Sar, B., Kombila, M., Swinne, D., Thérizol‐Ferly, M., Buisson, Y., & Richard-Lenoble, D. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1136-2 · Cited by 54
Datta, K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg399 · Cited by 54
Rhodotorula septicemia: case report and minireview
Petrocheilou, V., Prifti, H., Kostis, E., Papadimitriou, C., Dimopoulos, M. A., & Stamatelopoulos, S. F. (2001) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2001.00203.x · Cited by 48
Perniola, R., Faneschi, M. L., Manso, E., Pizzolante, M., Rizzo, A., Damiani, A. S., & Longo, R. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0114-2 · Cited by 43
Antifungal Susceptibility Testing Methods
Pfaller, M. A. (2005) · Current Drug Targets · doi:10.2174/138945005774912708 · Cited by 39
Self-citationGoldani, L. Z., Craven, D. E., & Sugar, A. M. (1995) · Medical Mycology · doi:10.1080/02681219580000531 · Cited by 39
In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole
Davey, K. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.217 · Cited by 39
Pfaller, M. A., Messer, S. A., Boyken, L. B., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.1.380-383.2004 · Cited by 39
Self-citationTay, S. T., Haryanty, T. T., Ng, K. P., Rohani, M. Y., & Hamimah, H. (2006) · Mycoses · doi:10.1111/j.1439-0507.2006.01242.x · Cited by 32
Morera, Y., Torres-Rodrı́guez, J. M., Jiménez-Cabello, T., & Baró, T. (2005) · Medical Mycology · doi:10.1080/13693780400029528 · Cited by 32
Yıldıran, Ş. T., Fothergill, A. W., Sutton, D. A., & Rinaldi, M. G. (2002) · Mycoses · doi:10.1046/j.1439-0507.2002.00765.x · Cited by 30
Management of Cryptococcal Meningitis in AIDS: The Need for Specific Studies in Developing Countries
Lortholary, O. (2007) · Clinical Infectious Diseases · doi:10.1086/518583 · Cited by 30
Aller, A. I., Claro, R. M., Castro, C., Serrano, C., Colom, M. F., & Martín‐Mazuelos, E. (2007) · Chemotherapy · doi:10.1159/000102585 · Cited by 20
Clarithromycin‐ResistantMycobacterium aviumStrain in a Clarithromycin‐Naive AIDS Patient
Goujard, C., Lebrun, L., Doucet‐Populaire, F., Vincent, V., & Nordmann, P. (1998) · Clinical Infectious Diseases · doi:10.1086/517055 · Cited by 4
Cited by
Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Self-citationEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationCandida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
Emerging opportunistic yeast infections
Miceli, M. H., Díaz, J. A., & Lee, S. A. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70218-8 · Cited by 811
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., Rennison, C., & Zaidi, M.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2009-01
- Volume
- 47
- Issue
- 1
- Pages
- 117-123
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2014904057
- Cited by
- 370
- References
- 86
- FWCI
- 25.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.